NEUSTAR
11.3.2020 09:02:09 CET | Business Wire | Press release
Today, Neustar®, Inc. , a global information services and technology company and leader in identity resolution, announced significant enhancements to its market-leading IP address geolocation service, UltraGeoPoint, (formerly known as IP GeoPoint) to help customers meet regulatory compliance requirements, strengthen network security and reduce risk while improving the user experience.
In response to the growing number of devices and people using IPv6 addresses, UltraGeoPoint now delivers enhanced insight into where an IPv6 address is located, how that IP address is connected to the Internet, and the metadata associated with it. By improving the performance of the global data collection network – expertly curated through advanced machine learning algorithms and a team of network geography analysts – Neustar customers can better target and geolocate IPv6 addresses.
“In today’s complex, constantly evolving digital landscape, organisations across all sectors need to be able to accurately evaluate an IP address and verify how it is connecting to the Internet,” said Brian McCann, president, Neustar Security Solutions. “With the right data to determine location and level of associated risk, they can quickly make informed decisions around network security, fraud mitigation, threat detection, and customer experience.”
The company has also expanded its city count by 50% through increasing the accuracy of identifying connection points and, in turn, location assignments. Additionally, the service now provides four times more granularity in the new IPv6 file, allowing customers to better identify IP address ranges to specific locations. This level of detail is especially important for businesses relying on IP geolocation and risk data to make decisions regarding OTT/streaming, regulatory compliance, fraud mitigation, and user experience – all of which require high-quality IPv6 data in the decision-making process.
“It is critical for online businesses to have the highest quality IP geolocation, organisation, and proxy decisioning data if they are going to be always on and ultra-secure. Our new UltraGeoPoint service enables our customers to obtain a deep view into IP location and connectivity to increase decisioning accuracy, reduce IP address risk, and improve security across their services and networks,” added McCann.
In addition to industry leading anonymous proxy detection and a proprietary closed loop customer geo feedback loop that ensures data quality, Neustar UltraGeoPoint IPv6 data meets strict Neustar data privacy standards providing support for GDPR and CCPA regulatory mandates.
Neustar’s other products also reap the benefits of the revamped UltraGeoPoint service, giving an extra layer of DDoS protection when combined with UltraDDoS Protect, and advanced traffic management and network optimisation when used in conjunction with UltraDNS.
You can find more information on Neustar UltraGeoPoint here .
-ENDS-
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, Security and Registry that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar .
###
View source version on businesswire.com: https://www.businesswire.com/news/home/20200311005030/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Echodyne Opens New Manufacturing Facility to Meet Surging Global Demand for Advanced MESA® Radar9.7.2026 15:00:00 CEST | Press release
New Washington State facility provides capacity to manufacture more than 30,000 radars annually, strengthening the U.S. defense industrial base As governments around the world accelerate investment in counter-unmanned aircraft systems (C-UAS) and short-range air defense, Echodyne today announced the opening of a new advanced radar manufacturing facility in Washington State, significantly expanding its manufacturing capacity to meet rapidly growing demand from U.S. and allied customers. With millions of drones manufactured and used by both sides in the Russian War in Ukraine, the need for enhanced safety for defense, national security, and critical infrastructure assets grows with every successful strike and interception. The low cost and high utility of drones dramatically alters the need for safety and security sensors. And as the low altitude economy takes off, hundreds of thousands of drones will perform a range of life-saving and commercial missions, requiring a sensor infrastructu
Orca Security Report: 99.9% of Fixable AI Vulnerabilities Remain Unpatched as AI Moves Into Production9.7.2026 15:00:00 CEST | Press release
Analysis of more than 1,200 production cloud environments provides a first-hand view into how organizations are embedding AI into business-critical workflows, exposing new security risks that traditional controls weren't built to address. Orca Security, a leader in cloud and AI security, today released its 2026 State of AI Security Report, offering a first-hand view into how AI is being deployed across more than 1,200 production cloud environments. The findings show AI is no longer limited to isolated pilots or developer experiments. Organizations are embedding AI into production applications, cloud services, and autonomous workflows faster than security programs can adapt. More than half (56%) of organizations have already deployed AI agents into production, while 51% use AI to build custom applications. At the same time, Orca found that 81% of organizations run vulnerable AI packages, and 99.9% of fixable AI vulnerabilities remain unpatched, highlighting how quickly AI has become ope
Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration9.7.2026 15:00:00 CEST | Press release
Cortechs.ai and Viz.ai partner to tackle multiple sclerosis and other neurodegenerative diseases across Viz.ai's health system network Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growing Viz Neuro Suite beyond its already market-leading neuro offerings. The collaboration will begin with a focus on multiple sclerosis (MS), integrating quantitative MRI analysis from NeuroQuant MS directly into Viz.ai's care coordination workflow, giving clinicians both the quantitative precision and the coordination infrastructure needed to identify and manage MS patients at scale. “Viz.ai's co
SCP Standard Capital Partners AG: Fabian Becker Appointed Chairman of the Management Board and CEO9.7.2026 14:51:00 CEST | Press release
The Supervisory Board of SCP Standard Capital Partners AG (WKN: A12UPJ | ISIN: DE000A12UPJ7 | XETRA ticker: CAP) resolved today to appoint Mr. Fabian Becker as Chairman of the Management Board and Chief Executive Officer (CEO), effective as of 9 July 2026. Ms. Stephanie Schettler-Köhler will remain a member of the Management Board and will assume the role of Chief Operating Officer (COO). View source version on businesswire.com: https://www.businesswire.com/news/home/20260709982268/en/
Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis9.7.2026 14:45:00 CEST | Press release
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances Teva’s Pivot to Growth strategy by expanding its biosimilars pipeline through strategic collaborations.Agreement reflects both companies’ commitment to broadening access to biologic medicines. Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus®1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma Biologics’ proven biosimilar development expertise with Teva’s commercial footprint and capabilities. This press release features multimedia. View the full release here: https://www.bus
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom